{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:03Z","timestamp":1792784943216,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hsiri Therapeutics","id":[{"id":"https:\/\/ror.org\/00dym4p25","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI054193"],"award-info":[{"award-number":["R37AI054193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI054193"],"award-info":[{"award-number":["R37AI054193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI054193"],"award-info":[{"award-number":["R37AI054193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The rapid rise of antimicrobial resistance, especially in\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    , highlights the urgent need for improved antibacterial agents. In 2019 alone, AMR caused an estimated 1.27 million deaths and contributed to nearly 5 million more globally. Here, we present the design, synthesis, and testing of modified ciprofloxacin analogs bearing nitrofuran, furan, and spirocyclic diamine moieties. Among these compounds, two showed a more than eight-fold increase in potency against ciprofloxacin-resistant\n                    <jats:italic>S.aureus<\/jats:italic>\n                    ISR14-002 compared to ciprofloxacin, demonstrating improved activity against a ciprofloxacin-resistant strain. In vivo testing using a\n                    <jats:italic>Galleria mellonella<\/jats:italic>\n                    infection model with\n                    <jats:italic>S. aureus<\/jats:italic>\n                    SG511 demonstrated that compound\n                    <jats:bold>12<\/jats:bold>\n                    conferred a survival benefit comparable to ciprofloxacin. Improved activity was most notable against Gram-positive bacteria, especially our target pathogen\n                    <jats:italic>S. aureus<\/jats:italic>\n                    . However, the spectrum of organism selectivity varied by analog, highlighting the effects of focused structural modification. These results suggest that the fluoroquinolone scaffold can be modified to circumvent ciprofloxacin resistance and expand its spectrum of activity, while retaining acceptable cellular toxicity.\n                  <\/jats:p>","DOI":"10.1038\/s41429-026-00963-7","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:11:13Z","timestamp":1791533473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro activity and comparative efficacy of novel nitrofuran-containing ciprofloxacin analogs against bacterial pathogens including ciprofloxacin-resistant Staphylococcus aureus"],"prefix":"10.1038","author":[{"given":"Kate","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reilly M.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Lawson-Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett C.","family":"Moraski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-8214","authenticated-orcid":false,"given":"Marvin J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"963_CR1","doi-asserted-by":"crossref","unstructured":"Antimicrobial Resistance Collaborators.Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355.","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"963_CR2","unstructured":"World Health Organization. More countries report rising levels of drug-resistant gonorrhoea, warns WHO. 2025. https:\/\/www.who.int\/news\/item\/19-11-2025-more-countries-report-rising-levels-of-drug-resistant-gonorrhoea--warns-who."},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/MOH.0000000000000394","volume":"25","author":"JS Stevens","year":"2018","unstructured":"Stevens JS, Criss AK. Pathogenesis of Neisseria gonorrhoeae in the female reproductive tract: neutrophilic host response, sustained infection, and clinical sequelae. Curr Opin Hematol. 2018;25:13\u201321.","journal-title":"Curr Opin Hematol"},{"key":"963_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2016.08.008","volume":"216","author":"DG Tsevat","year":"2017","unstructured":"Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2017;216:1\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"963_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fmicb.2020.01299","volume":"11","author":"F Guvenc","year":"2020","unstructured":"Guvenc F, Kaul R, Gray-Owen SD. Intimate Relations: Molecular and Immunologic Interactions Between Neisseria gonorrhoeae and HIV-1. Front Microbiol. 2020;11:1299.","journal-title":"Front Microbiol"},{"key":"963_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s40121-021-00481-z","volume":"10","author":"J Whelan","year":"2021","unstructured":"Whelan J, Eeuwijk J, Bunge E, Beck E. Systematic Literature Review and Quantitative Analysis of Health Problems Associated with Sexually Transmitted Neisseria gonorrhoeae Infection. Infect Dis Ther. 2021;10:1887\u2013905.","journal-title":"Infect Dis Ther"},{"key":"963_CR7","doi-asserted-by":"publisher","first-page":"7767","DOI":"10.3390\/jcm12247767","volume":"12","author":"AR Raccagni","year":"2023","unstructured":"Raccagni AR, Ranzenigo M, Bruzzesi E, Maci C, Castagna A, Nozza S. Neisseria gonorrhoeae Antimicrobial Resistance: The Future of Antibiotic Therapy. J Clin Med. 2023;12:7767.","journal-title":"J Clin Med"},{"key":"963_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2165\/00003495-199651060-00010","volume":"51","author":"R Davis","year":"1996","unstructured":"Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51:1019\u201374.","journal-title":"Drugs"},{"key":"963_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3109\/14756360903373350","volume":"25","author":"PC Sharma","year":"2010","unstructured":"Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J Enzym Inhib Med Chem. 2010;25:577\u201389.","journal-title":"J Enzym Inhib Med Chem"},{"key":"963_CR10","first-page":"12","volume":"82","author":"DC Hooper","year":"1987","unstructured":"Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action of and resistance to ciprofloxacin. Am J Med. 1987;82:12\u201320.","journal-title":"Am J Med"},{"key":"963_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1025633","volume":"10","author":"A Shariati","year":"2022","unstructured":"Shariati A, Arshadi M, Khosrojerdi MA, Abedinzadeh M, Ganjalishahi M, Maleki A, et al. The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic. Front Public Health. 2022;10:1025633.","journal-title":"Front Public Health"},{"key":"963_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107773","volume":"153","author":"Khanna","year":"2024","unstructured":"Khanna, Kumar A, Rana N, Jyoti R, Sharma, Muskan A, et al. Fluoroquinolones tackling antimicrobial resistance: Rational design, mechanistic insights and comparative analysis of norfloxacin vs ciprofloxacin derivatives. Bioorg Chem. 2024;153:107773.","journal-title":"Bioorg Chem"},{"key":"963_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2174\/1568026622666220317162132","volume":"22","author":"Z Wenhua","year":"2022","unstructured":"Wenhua Z, Danxia L, Li G, Shuang G, Pengfei H, Hua B. The Antibacterial Potential of Ciprofloxacin Hybrids against Staphylococcus aureus. Curr Top Med Chem. 2022;22:1020\u201334.","journal-title":"Curr Top Med Chem"},{"key":"963_CR14","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.3390\/ijms25094919","volume":"25","author":"V Khwaza","year":"2024","unstructured":"Khwaza V, Mlala S, Aderibigbe BA. Advancements in Synthetic Strategies and Biological Effects of Ciprofloxacin Derivatives: A Review. Int J Mol Sci. 2024;25:4919.","journal-title":"Int J Mol Sci"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1128\/AAC.45.10.2703-2709.2001","volume":"45","author":"T Lu","year":"2001","unstructured":"Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, et al. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45:2703\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"963_CR16","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.3390\/molecules27154864","volume":"27","author":"A Lukin","year":"2022","unstructured":"Lukin A, Chudinov M, Vedekhina T, Rogacheva E, Kraeva L, Bakulina O, et al. Exploration of Spirocyclic Derivatives of Ciprofloxacin as Antibacterial Agents. Molecules. 2022;27:4864.","journal-title":"Molecules"},{"key":"963_CR17","first-page":"432","volume":"58","author":"A Foroumadi","year":"2003","unstructured":"Foroumadi A, Ashraf-Askari R, Moshafi MH, Emami S, Zeynali A. Synthesis and in vitro antibacterial activity of N-[5-(5-nitro-2-furyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolone derivatives. Pharmazie. 2003;58:432\u20133.","journal-title":"Pharmazie"},{"key":"963_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0223-5234(03)00148-X","volume":"38","author":"A Foroumadi","year":"2003","unstructured":"Foroumadi A, Mansouri S, Kiani Z, Rahmani A. Synthesis and in vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolones. Eur J Med Chem. 2003;38:851\u20134.","journal-title":"Eur J Med Chem"},{"key":"963_CR19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0014-827X(03)00191-5","volume":"58","author":"A Foroumadi","year":"2003","unstructured":"Foroumadi A, Soltani F, Moshafi MH, Ashraf-Askari R. Synthesis and in vitro antibacterial activity of some N-(5-aryl-1,3,4-thiadiazole-2-yl)piperazinyl quinolone derivatives. Farmaco. 2003;58:1023\u20138.","journal-title":"Farmaco"},{"key":"963_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ardp.200600108","volume":"339","author":"A Foroumadi","year":"2006","unstructured":"Foroumadi A, Mansouri S, Emami S, Mirzaei J, Sorkhi M, Saeid-Adeli N, et al. Synthesis and antibacterial activity of nitroaryl thiadiazole-levofloxacin hybrids. Arch Pharm. 2006;339:621\u20134.","journal-title":"Arch Pharm"},{"key":"963_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2022.108344","volume":"240","author":"M Sadeghi","year":"2022","unstructured":"Sadeghi M, Sarvi S, Emami S, Khalilian A, Hosseini SA, Montazeri M, et al. Evaluation of anti-parasitic activities of new quinolones containing nitrofuran moiety against Toxoplasma gondii. Exp Parasitol. 2022;240:108344.","journal-title":"Exp Parasitol"},{"key":"963_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/biom14111419","volume":"14","author":"G Suleiman","year":"2024","unstructured":"Suleiman G, El Brahmi N, Guillaumet G, El Kazzouli S. Advances in the Synthesis and Biological Applications of Enoxacin-Based Compounds. Biomolecules. 2024;14:1419.","journal-title":"Biomolecules"},{"key":"963_CR23","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1007\/s00044-013-0581-9","volume":"22","author":"S Emami","year":"2013","unstructured":"Emami S, Shahrokhirad N, Foroumadi A, Faramarzi MA, Samadi N, Soltani-Ghofrani N. 7-Piperazinylquinolones with methylene-bridged nitrofuran scaffold as new antibacterial agents. Med Chem Res. 2013;22:5940\u20137.","journal-title":"Med Chem Res"},{"key":"963_CR24","doi-asserted-by":"publisher","first-page":"e1009663","DOI":"10.1371\/journal.ppat.1009663","volume":"17","author":"VVH Le","year":"2021","unstructured":"Le VVH, Rakonjac J. Nitrofurans: Revival of an \u201cold\u201d drug class in the fight against antibiotic resistance. PLoS Pathog. 2021;17:e1009663.","journal-title":"PLoS Pathog"},{"key":"963_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1128\/AAC.45.1.324-326.2001","volume":"45","author":"GG Zhanel","year":"2001","unstructured":"Zhanel GG, Hoban DJ, Karlowsky JA. Nitrofurantoin is active against vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2001;45:324\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"963_CR26","first-page":"Dc19","volume":"11","author":"S Meena","year":"2017","unstructured":"Meena S, Mohapatra S, Sood S, Dhawan B, Das BK, Kapil A. Revisiting Nitrofurantoin for Vancomycin Resistant Enterococci. J Clin Diagn Res. 2017;11:Dc19\u201322.","journal-title":"J Clin Diagn Res"},{"key":"963_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jemermed.2011.08.018","volume":"43","author":"A Wackett","year":"2012","unstructured":"Wackett A, Nazdryn A, Spitzer E, Singer AJ. MRSA Rates and Antibiotic Susceptibilities from Skin and Soft Tissue Cultures in a Suburban ED. J Emerg Med. 2012;43:754\u20137.","journal-title":"J Emerg Med"},{"key":"963_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/jac\/33.suppl_A.23","volume":"33","author":"CC McOsker","year":"1994","unstructured":"McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother. 1994;33:23\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"963_CR29","first-page":"121","volume":"34","author":"B Khamari","year":"2025","unstructured":"Khamari B, Bulagonda EP. Unlocking Nitrofurantoin: Understanding Molecular Mechanisms of Action and Resistance in Enterobacterales. Med Princ Pr. 2025;34:121\u201337.","journal-title":"Med Princ Pr"},{"key":"963_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2011.67","volume":"64","author":"GC Moraski","year":"2011","unstructured":"Moraski GC, Thanassi JA, Podos SD, Pucci MJ, Miller MJ. One-step syntheses of nitrofuranyl benzimidazoles that are active against multidrug-resistant bacteria. J Antibiot. 2011;64:667\u201371.","journal-title":"J Antibiot"},{"key":"963_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22592","volume":"9","author":"S Al-Taweel","year":"2023","unstructured":"Al-Taweel S, Al-Saraireh Y, Al-Trawneh S, Alshahateet S, Al- Tarawneh R, Ayed N, et al. Synthesis and biological evaluation of ciprofloxacin \u2013 1,2,3-triazole hybrids as antitumor, antibacterial, and antioxidant agents. Heliyon. 2023;9:e22592.","journal-title":"Heliyon"},{"key":"963_CR32","doi-asserted-by":"publisher","first-page":"17051","DOI":"10.1039\/D4RA01332H","volume":"14","author":"UK Patel","year":"2024","unstructured":"Patel UK, Tiwari P, Tilak R, Joshi G, Kumar R, Agarwal A. Synthesis of ciprofloxacin-linked 1,2,3-triazole conjugates as potent antibacterial agents using click chemistry: exploring their function as DNA gyrase inhibitors via in silico- and in vitro-based studies. RSC Adv. 2024;14:17051\u201370.","journal-title":"RSC Adv"},{"key":"963_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1039\/D4MD00623B)","volume":"16","author":"O Ommi","year":"2025","unstructured":"Ommi O, Dhopat PS, Sau S, Estharla MR, Nanduri S, Kalia NP, et al. Design, synthesis, and biological evaluation of pyrazole\u2013ciprofloxacin hybrids as antibacterial and antibiofilm agents against Staphylococcus aureus. RSC Med Chem. 2025;16:420\u20138. https:\/\/doi.org\/10.1039\/D4MD00623B).","journal-title":"RSC Med Chem"},{"key":"963_CR34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s11030-022-10528-z","volume":"27","author":"HHH Mohammed","year":"2023","unstructured":"Mohammed HHH, Ali DME, Badr M, Habib AGK, Mahmoud AM, Farhan SM, et al. Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors. Mol Divers. 2023;27:1751\u201365.","journal-title":"Mol Divers"},{"key":"963_CR35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cmdc.201700170","volume":"12","author":"GC Moraski","year":"2017","unstructured":"Moraski GC, Bristol R, Seeger N, Boshoff HI, Tsang PS, Miller MJ. Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds. ChemMedChem. 2017;12:1108\u201315.","journal-title":"ChemMedChem"},{"key":"963_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biopha.2007.10.004","volume":"63","author":"P Senthilkumar","year":"2009","unstructured":"Senthilkumar P, Dinakaran M, Yogeeswari P, China A, Nagaraja V, Sriram D. Antimycobacterial activities of novel fluoroquinolones. Biomed Pharmacother. 2009;63:27\u201335.","journal-title":"Biomed Pharmacother"},{"key":"963_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.136810","volume":"1295","author":"I Rehman","year":"2024","unstructured":"Rehman I, Gul S, Akhtar M, Amin R, fatima R. Design, synthesis and docking studies of ciprofloxacin analogues as potential antimicrobial agents against resistant pathogens. J Mol Struct. 2024;1295:136810.","journal-title":"J Mol Struct"},{"key":"963_CR38","volume":"11","author":"M Yano","year":"2024","unstructured":"Yano M, Lawson-Rulli JM, Coates RM, Heldring J, Miller MJ, Liu R. Improved in vitro potency of Clofazimine derivatives against Neisseria species. Eur J Med Chem Rep. 2024;11:100147.","journal-title":"Eur J Med Chem Rep"},{"key":"963_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1021\/acsinfecdis.5c00943","volume":"12","author":"R Liu","year":"2026","unstructured":"Liu R, Miller PA, Miller MJ. Antibiotic Repurposing: Conjugation of the Gram-Positive Only Peptide Antibiotic Bacitracin to a Bis-Catechol Siderophore Mimetic Imparts Potent Activity against Multi-Drug Resistant Acinetobacter baumannii. ACS Infect Dis. 2026;12:1254\u20139.","journal-title":"ACS Infect Dis"},{"key":"963_CR40","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.21769\/BioProtoc.4480","volume":"12","author":"PR Stempinski","year":"2022","unstructured":"Stempinski PR, Smith DFQ, Casadevall A. Cryptococcus neoformans Virulence Assay Using a Galleria mellonella Larvae Model System. Bio Protoc. 2022;12:4480.","journal-title":"Bio Protoc"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00963-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00963-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:03:08Z","timestamp":1791579788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00963-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":40,"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1038\/s41429-026-00963-7","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships that may be considered potential competing interests:\u00a0MY is Senior Vice President of Biology at Hsiri Therapeutics. JL-R and RMC are research scientists employed by Hsiri Therapeutics. MJM is the CSO of Hsiri Therapeutics. GCM is a consultant for Hsiri Therapeutics. KM was supported by funding at Montana State University provided by Hsiri Therapeutics.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}